Category Archives: Obesity

NPC Archive Item: EMA to review liver safety of orlistat

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 12 October 2011 The European Medicines Agency (EMA) has announced a review of orlistat, to determine whether the very rare cases of liver injury associated with its use have […]

NPC Archive Item: Liraglutide▼ for the treatment of obesity

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 04 March 2010 Obese, non-diabetic patients received one of four doses of liraglutide▼ subcutaneously once a day versus open-label orlistat orally three times a day in a European, phase […]

NPC Archive Item: Drug Safety Update from MHRA/CHM (February 2010)

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 19 February 2010 The MHRA and CHM have published the February edition of Drug Safety Update This edition includes […]

NPC Archive Item: Sibutramine (Reductil) licence suspended throughout Europe

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 January 2010 The MHRA has announced that the licence for sibutramine has been suspended throughout Europe. This follows a review which considered the increased risk of non-fatal heart […]

NPC Archive Item: FDA reviews the safety of Orlistat

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 September 2009 The FDA is reviewing the safety information for Orlistat following reports of serious liver injury. However, no definite association between liver injury and orlistat has been […]

NPC Archive Item: Rimonabant marketing authorisation to be suspended

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The MHRA has announced the Europe-wide suspension of the Marketing Authorisation for rimonabant▼ (Acomplia®) following recommendations from the EMEA’s Committee for Medicinal Products for Human Use (CMHP). The CMHP […]

NPC Archive Item: NICE Final Appraisal Determination recommends rimonabant▼

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE has published a Final Appraisal Determination (FAD) for rimonabant▼ for the treatment of overweight and obese patients. In the Appraisal Consultation Document, published in December 2007, the Appraisal […]

NPC Archive Item: Preliminary recommendations from NICE reject rimonabant

NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. Preliminary recommendations from NICE reject rimonabant The NICE Appraisal Committee has developed preliminary recommendations on the use of rimonabant for the treatment of overweight and obese adults, which state […]